Clinical trials: Everolimus
Liver Transplantation
Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients
This trial was designed to address important issues that impact recipients of liver allografts as well as clinicians, ie, renal function, reduction or discontinuation of tacrolimus early post-transplantation, and progression rate…
- Trial name
- RAD (NCT00622869)
- Testing
- Tacrolimus (reduced tacrolimus), Tacrolimus (tacrolimus elimination), Tacrolimus (tacrolimus control)
- Where
- 91 sites in United States, Argentina and 17 more
- Volunteers
- 719 people
- Sponsor
- Novartis Pharmaceuticals
Liver Transplant
Liver Transplantation With Tregs at MGH
This is a single-center, prospective, open-label, non-randomized clinical trial exploring cellular therapy to facilitate immunosuppression withdrawal in liver transplant recipients.
- Trial name
- LITTMUS-MGH (NCT03577431)
- Testing
- arTreg-CSB, leukapheresis, cyclophosphamide
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Coronary Artery Disease
Zotarolimus and Everolimus-Eluting Stents ProsPectively Compared in Real World
The zotarolimus-eluting Endeavor Resolute stent is not inferior to the everolimus- eluting Xience V stent platform regarding a composite of cardiac death, myocardial infarction or target lesion revascularisation in a real-world…
- Trial name
- ZEPPELIN (NCT00768846)
- Testing
- Endeavor Resolute Stent, Xience V Stent
- Where
- 2 sites in Germany
- Volunteers
- 2,600 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Liver Cancer
Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease
The goal of this clinical research study is to find the highest tolerable dose of the combination of everolimus with TheraSphere that can be given to patients with advanced NETs that have spread to the liver.
- Trial name
- NCT01864070
- Testing
- TheraSphere, Everolimus, Phone Call
- Sponsor
- M.D. Anderson Cancer Center
Chronic Allograft Dysfunction in Renal Transplantation
Everolimus Rescue Immunosuppression in the Treatment of Chronic Allograft Dysfunction in Renal Transplant Recipients
Despite the remarkable improvement in short-term patient and graft survival among the recipients of kidney transplants, the progressive renal dysfunction (chronic allograft dysfunction) accompanied by chronic interstitial…
- Trial name
- NCT01046045
- Testing
- everolimus
- Where
- Hong Kong
- Volunteers
- 17 people
- Sponsor
- Chinese University of Hong Kong
Respiratory Tract Infections
Dose Finding Study to Determine if BEZ235 Alone or in Combination With RAD001 Decreases the Incidence of Respiratory Tract Infections in the Elderly
The purpose of this study is to evaluate the efficacy, tolerability, and safety of BEZ235 alone and in combination with RAD001 to support further development to reduce the incidence of respiratory tract infections (RTIs) in…
- Trial name
- NCT03373903
- Testing
- BEZ235, BEZ235 plus everolimus (RAD001)
- Where
- United States
- Volunteers
- 652 people, healthy volunteers welcome
- Sponsor
- Restorbio Inc.
Coronary Artery Disease
ComparisiOn of Neointimal coVerage betwEen ZES and EES Using OCT at 3 Months
This study try to 1) evaluate the neointimal coverage and malapposition at 3 month after new zotarolimus eluting stent (Endeavor resolute) and everolimus eluting stent (Xience) implantation and 2) compare them between ZES…
- Trial name
- COVER OCT-II (NCT01091740)
- Testing
- ZES resolute (Endeavor Resolute), EES (Xience)
- Where
- 2 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- Yonsei University
Acute Myocardial Infarction
Everolimus Stent in Myocardial Infarction
Randomized trial to test the efficacy and safety of newer Drug Eluting Stent generation in patient with acute myocardial infarction treated with primary percutaneous coronary intervention (PCI)
- Trial name
- RaCES-MI (NCT01684982)
- Testing
- everolimus eluting stent, sirolimus eluting stent
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- San Giuseppe Moscati Hospital
Coronary Artery Disease
Assessment of Cutting-Balloon Angioplasty With Everolimus-Eluting Stent(EES) in the Treatment of Coronary Calcified Lesion(CCL) Guided by Intravascular Ultrasonography(IVUS)
The study seeks to address the clinical question of how effectively a novel cutting balloon (Wolverine™) can modify calcified lesions for stent implantation in comparison with a non-compliant (NC) balloon, particularly when used…
- Trial name
- NCT06177808
- Testing
- Wolverine cutting balloon, Non-compliant balloon
- Where
- South Korea
- Volunteers
- 250 people
- Sponsor
- Soonchunhyang University Hospital
Restenosis
Treatment of Coronary In-Stent Restenosis
The purpose of this study is to compare efficacy of coronary in-stent restenosis therapy using drug eluting paclitaxel-coated balloon catheters with the latest generation of drug eluting stents releasing everolimus.
- Trial name
- TIS (NCT01735825)
- Testing
- paclitaxel-coated balloon catheter with Iopromide coating, drug eluting stent with everolimus, seal-wing paclitaxel-eluting balloon catheter
- Where
- Czechia
- Volunteers
- 199 people
- Sponsor
- University Hospital Ostrava
Neuroendocrine Carcinoma
Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine Carcinoma
Primary Objectives: To determine the effect of Avastin on tumor blood flow as determined by functional computed tomography (CT) in patients with low or intermediate grade neuroendocrine carcinoma.
- Trial name
- NCT00607113
- Testing
- Avastin, RAD001
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- M.D. Anderson Cancer Center
Coronary Artery Disease
NeoVas Bioresorbable Coronary Scaffold Randomized Controlled Trial
The NeoVas Bioresorbable Coronary Scaffold Randomized Controlled Trial is a prospective, multi-center, randomized trial. The study compares NeoVas sirolimus-eluting bioresorbable coronary scaffold with XIENCE PRIME Everolimus…
- Trial name
- NCT02305485
- Testing
- NeoVas BCS, XIENCE PRIME EECSS
- Where
- 27 sites in China
- Volunteers
- 560 people
- Sponsor
- Lepu Medical Technology (Beijing) Co., Ltd.
Coronary Artery Disease, Angina Pectoris
The OCT SORT-OUT VIII Study
The purpose of this study is to compare early vessel healing after implantation of SYNERGY drug eluting stent (DES) or BioMatrix NeoFlex DES at one and three months in two cohorts.
- Conditions
- Coronary Artery Disease, Angina Pectoris, Myocardial Infarction
- Trial name
- OCT SORT-OUT (NCT02253108)
- Testing
- Everolimus eluting bioresorbable polymer stent, Biolimus eluting bioresorbable polymer stent
- Where
- 2 sites in Denmark
- Volunteers
- 160 people
- Sponsor
- Aarhus University Hospital Skejby
Lung Transplantation
Efficacy Regarding Renal Function of Everolimus in Combination With Specific Standard Immunosuppressive Regimen Lung Transplant Recipients
This trial evaluated the efficacy of an everolimus-based quadruple low immunosuppressive regimen versus a standard immunosuppressive regimen concerning kidney function in lung transplant recipients.
- Trial name
- 4EVERLUNG (NCT01404325)
- Testing
- standard therapy, Everolimus
- Where
- 9 sites in Germany
- Volunteers
- 130 people
- Sponsor
- Novartis Pharmaceuticals
Colorectal Cancer
Everolimus in Treating Patients With Advanced or Metastatic Colorectal Cancer That Did Not Respond to Previous Therapy
RATIONALE: Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00390364
- Testing
- everolimus, antiangiogenesis therapy, biopsy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Metastatic Breast Cancer
Lapatinib and RAD-001 for HER2 Positive Metastatic Breast Cancer
By doing this study, researchers hope to learn the effectiveness of the combination of Lapatinib and RAD-001 for treating patients who have progressed on previous therapies.
- Trial name
- NCT01283789
- Testing
- Lapatinib and RAD-001
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Kansas Medical Center
Peripheral Vascular Disease, Peripheral Arterial Disease
EVERO Drug-coated Balloon (DCB) Randomized Trial
The primary objective of the study is to evaluate the long-term safety and effectiveness of the Advance Evero™ 18 Everolimus-coated Percutaneous Transluminal Angioplasty Balloon Catheter (hereafter referred to as the Evero…
- Trial name
- NCT07144150
- Testing
- Evero DCB, Paclitaxel DCB
- Where
- 12 sites in United States
- Volunteers
- 410 people
- Sponsor
- Cook Research Incorporated
Advanced Breast Cancer, ER-positive Breast Cancer
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
This trial will study a type of advanced breast cancer (ABC) defined as endocrine receptor (ER)-positive/human epidermal growth factor receptor 2(HER2)-negative and estrogen receptor 1 (ESR1)-mutated.
- Conditions
- Advanced Breast Cancer, ER-positive Breast Cancer, HER2-negative Breast Cancer, ESR1 Gene Mutation
- Trial name
- ADELA (NCT06382948)
- Testing
- Everolimus, Elacestrant, Auxiliary Medicinal Product - Dexamethasone
- Where
- 104 sites in Austria, Brazil and 7 more
- Volunteers
- 300 people
- Sponsor
- MedSIR
Vascular Malformations, Arteriovenous Malformations
A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies
Background and Objectives Vascular anomalies are a heterogeneous group of disorders classified into vascular tumors and vascular malformations according to the ISSVA classification.
- Conditions
- Vascular Malformations, Arteriovenous Malformations, Venous Malformation, Lymphangioma
- Trial name
- NCT07477548
- Testing
- Everolimus
- Volunteers
- 67 people
- Sponsor
- Yonsei University
Metastatic Clear Cell Renal Cancer
Dose Escalation Study Investigating Everolimus and Dovitinib in Metastatic Clear Cell Renal Cancer
When kidney cancer spreads beyond the kidney, it is known as metastatic kidney cancer. This is very difficult to treat and almost all patients will die of their disease within 3 years.
- Trial name
- DEVELOP (NCT01714765)
- Testing
- Dovitinib, Everolimus
- Where
- United Kingdom
- Volunteers
- 17 people
- Sponsor
- Queen Mary University of London